Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA is aware of media reports of delta-8 THC products getting consumers “high.” brownies, gummies).

THC 105

THC Pets Events Hemp 105

Canna Law Blog

APRIL 13, 2019

The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.” Specifically, the agency fears that.

CBD 91

CBD Safety Topical Food 91

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Recent data suggest the US science knowledge is about the global average.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. For media inquiries please contact: Michael Sharp. Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

The Blunt Truth

AUGUST 13, 2019

On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The FDA is collecting data to fill these gaps. The public hearing attracted over 100 speakers and 2000 participants.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “In

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

MAY 6, 2022

The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Taking CBD can relieve pain.”. “In

THC 52

THC CBD Media Food 52

The Blunt Truth

MAY 26, 2020

In his statement, Commissioner Hahn noted that the FDA was working on: 1) continuing to educate the public on the risks of CBD; 2) seeking reliable data on the safety and benefits of CBD, including opening the public docket on the matter; and 3) monitoring the marketplace for the sale and marketing of unapproved drugs.

CBD 103

CBD Hemp Programs Food 103

Cannabis Law Report

JANUARY 13, 2020

Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Media Enquiries: Sam Brown Inc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

CannaMD

AUGUST 19, 2020

Unlike THC, CBD has a high margin of safety and is well tolerated pharmacologically even after treatments of up to 1500 mg/day for two weeks in both animals and humans, which suggests its feasibility to reduce SARS-CoV2 induced lung inflammation/pathology and disease severity. .” Our initial data suggest that some C.

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.”.

CBD 40

CBD Research and Development Safety Therapy 40

Veriheal

AUGUST 12, 2021

The authors added that in spite of the growing availability and diversity of alternative cannabinoid products like artisanal CBD—as opposed to pharmaceutical CBD—existing studies assessing their efficacy and/or safety are extremely rare. The majority of patients (74%) were Caucasian and more than half (55%) identified as female.

Epilepsy 66

Epilepsy Pharmaceutical Patients Sleep 66

Cannabis Law Report

FEBRUARY 17, 2022

Mycotoxins are contaminants that licensees are required to screen for to uphold public health, safety, and welfare. Mycotoxins are contaminants that licensees are required to screen for to uphold public health, safety, and welfare. There are currently no ISO-accredited Independent Testing Laboratories located on Nantucket.

Marijuana 52

Marijuana Seed-To-Sale Safety Patients 52

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Joint Blog

JULY 25, 2020

Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. FDA is the government agency that ensures the safety and quality of foods, drugs, cosmetics, and other like products marketed in the United States. CBD Legal and Safety Issues An FDA report presented to the U.S.

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

DECEMBER 14, 2021

There are 28 million people suffering from chronic pain in the UK and this range of formulations offers pain doctors the best and most comprehensive selection of cannabinoid treatment options for their patients. We are proud to leverage our proprietary IP, formulation expertise, safety surveillance and patient reported data from the U.S.

Extraction 52

Extraction Patients Medicine Tincture 52

Cannabis Law Report

JULY 24, 2019

1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products.

CBD 51

CBD Tincture Pets Chronic Pain 51

Cannabis Law Report

JULY 20, 2019

In New Jersey, there are nearly 50,000 registered medical marijuana patients and only six Alternative Treatment Centers (ATCs) currently operating. Ability to meet the overall health needs of qualified patients and safety of the public. Ability to provide appropriate research data. By: Kristin Jordan , Senior Counsel.

Law 40

Law Marijuana Education Cultivation 40

Cannabis Law Report

JULY 23, 2019

It is important that they conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinical trials. Some states require mandatory warning statements in advertisements for medical cannabis. a playground, recreation centre, library or public park.

Law 40

Law Clinical Trials CBD Edibles 40

SpeedWeed

MARCH 5, 2021

Several factors are in play, according to union officials and labor experts: The pandemic increased employee anxiety and concerns about workplace health and safety, opening the window for union organizing. In Massachusetts, workers at a New England Treatment Access (NETA) dispensary in Brookline soundly rejected the union by a 30-9 vote.

Marijuana 52

Marijuana Dispensary Retail Business 52

Cannabis Law Report

OCTOBER 29, 2021

The primary endpoint of this Phase 1 trial was safety and tolerability. We expect to report this data as it becomes available and after submission to the FDA. social media: www.igcinc.us / www.igcpharma.com. in thousands, except share data). . . . in thousands, except loss per share and share data). . .

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.

CBD 144

CBD Seed-To-Sale Food Access 144

SpeedWeed

JULY 19, 2021

The document in question was a 2020 safety study of the vape cartridge additive phytol. The data contained in that report has rocked the cannabis vaping world. The data was far worse than he imagined. Phytol, according to the data in the study, appeared unsafe to inhale. Its contents floored him. What is phytol?

Vaping 52

Vaping Terpenes Data Research and Development 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 9, 2021

The study involved 100 treatment-resistant patients and were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. At 12 months, 59% of the patients who received the psilocybin treatment remained abstinent, while only 28% of those who received the nicotine patch remained abstinent.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

The Cannigma

MARCH 2, 2022

Anthony is the founder of the Trav Media Group. EG: I’m here at the moment with Anthony Travagliante of Trav Media Group. We were named differently back then now with Trav Media Group. Can you tell us a bit more about what you offer at the Trav Media Group across the board? I’ll do social media for you.

Wellness and Beauty 52

Wellness and Beauty Cannabis Media Patients 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

DECEMBER 8, 2021

Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. Media: Laura Radocaj.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

SpeedWeed

MARCH 4, 2021

Since the data does not support the tired narrative that legalization will inevitably lead to a spike in teenage use, opponents have pivoted to discuss increased behavioral health issues among teens based on potency. As usual, though, the evidence materially depends on personal anecdotes, scare tactics and a lack of actual scientific data.

Business 52

Business Concentrates Education Research and Development 52

The Cannigma

JANUARY 19, 2022

The resulting prejudice can often discourage folks from seeking out medical cannabis as an option, and can even affect state legislature, forcing patients to overcome unnecessary and prohibitive obstacles in order to receive the treatment they need. 30,000 max for LinkedIn and –. HD: Thanks and thank you for having me on here.

Patients 83

Patients Compliance Compliance Cannabis 83

Cannabis Law Report

JANUARY 21, 2019

An electronic storage system is any system for preparing or keeping your records either by electronic imaging or by transfer to an electronic storage media. All electronic storage systems must provide a complete and accurate record of your data that is accessible to the IRS. . trace system; .

Seed-To-Sale 40

Seed-To-Sale Business Compliance Compliance 40